Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Atrial Fibrillation | 24 | 2023 | 180 | 8.250 |
Why?
|
Cardiovascular Diseases | 21 | 2023 | 402 | 5.710 |
Why?
|
Stroke | 21 | 2023 | 293 | 4.670 |
Why?
|
Heart Failure | 8 | 2023 | 202 | 2.700 |
Why?
|
Female | 78 | 2023 | 16197 | 2.210 |
Why?
|
Aortic Valve Stenosis | 4 | 2023 | 23 | 2.190 |
Why?
|
Transcatheter Aortic Valve Replacement | 4 | 2023 | 27 | 2.170 |
Why?
|
Humans | 103 | 2023 | 29337 | 2.110 |
Why?
|
Anticoagulants | 7 | 2022 | 100 | 2.090 |
Why?
|
Myocardial Infarction | 11 | 2023 | 172 | 1.950 |
Why?
|
Healthcare Disparities | 6 | 2020 | 75 | 1.870 |
Why?
|
Coronary Artery Disease | 8 | 2022 | 123 | 1.860 |
Why?
|
Risk Factors | 31 | 2023 | 2443 | 1.820 |
Why?
|
Sex Factors | 18 | 2022 | 496 | 1.740 |
Why?
|
Pregnancy Complications, Cardiovascular | 6 | 2023 | 17 | 1.700 |
Why?
|
Hospital Mortality | 8 | 2023 | 141 | 1.660 |
Why?
|
Cardiologists | 2 | 2023 | 14 | 1.640 |
Why?
|
Exercise | 7 | 2022 | 468 | 1.510 |
Why?
|
Cardiology | 5 | 2022 | 73 | 1.490 |
Why?
|
Cognitive Dysfunction | 5 | 2023 | 938 | 1.480 |
Why?
|
Risk Assessment | 14 | 2022 | 679 | 1.430 |
Why?
|
Sex Characteristics | 7 | 2023 | 132 | 1.390 |
Why?
|
Hospitalization | 8 | 2021 | 317 | 1.350 |
Why?
|
Myocardial Ischemia | 4 | 2022 | 50 | 1.330 |
Why?
|
Life Style | 8 | 2020 | 211 | 1.330 |
Why?
|
Women's Health | 4 | 2020 | 246 | 1.290 |
Why?
|
Primary Prevention | 4 | 2022 | 38 | 1.260 |
Why?
|
Cardiovascular System | 3 | 2022 | 14 | 1.250 |
Why?
|
Acute Kidney Injury | 3 | 2023 | 49 | 1.250 |
Why?
|
Male | 48 | 2023 | 15621 | 1.250 |
Why?
|
Aged | 40 | 2022 | 9448 | 1.240 |
Why?
|
Quality of Life | 8 | 2023 | 662 | 1.240 |
Why?
|
United States | 27 | 2023 | 2333 | 1.190 |
Why?
|
Physicians, Women | 3 | 2022 | 18 | 1.180 |
Why?
|
Hydroxymethylglutaryl-CoA Reductase Inhibitors | 4 | 2020 | 63 | 1.170 |
Why?
|
Catheter Ablation | 3 | 2022 | 78 | 1.110 |
Why?
|
Pacemaker, Artificial | 3 | 2023 | 48 | 1.100 |
Why?
|
Angiotensin-Converting Enzyme Inhibitors | 2 | 2020 | 26 | 1.050 |
Why?
|
Health Status Disparities | 4 | 2019 | 69 | 1.040 |
Why?
|
Adrenergic beta-Antagonists | 2 | 2020 | 42 | 1.040 |
Why?
|
Arrhythmias, Cardiac | 6 | 2019 | 149 | 1.040 |
Why?
|
Defibrillators, Implantable | 3 | 2021 | 30 | 1.000 |
Why?
|
Anti-Arrhythmia Agents | 7 | 2022 | 104 | 0.970 |
Why?
|
Middle Aged | 32 | 2022 | 9823 | 0.960 |
Why?
|
American Heart Association | 4 | 2023 | 29 | 0.950 |
Why?
|
Ischemic Attack, Transient | 2 | 2023 | 20 | 0.940 |
Why?
|
Terminal Care | 1 | 2023 | 27 | 0.890 |
Why?
|
Echocardiography, Doppler, Color | 2 | 2019 | 13 | 0.880 |
Why?
|
Myocarditis | 1 | 2022 | 6 | 0.880 |
Why?
|
Premature Birth | 1 | 2022 | 6 | 0.870 |
Why?
|
Heart Defects, Congenital | 1 | 2023 | 30 | 0.870 |
Why?
|
Breast Neoplasms | 3 | 2021 | 329 | 0.840 |
Why?
|
Pregnancy | 9 | 2023 | 403 | 0.820 |
Why?
|
Coronavirus | 1 | 2021 | 2 | 0.810 |
Why?
|
Electrocardiography | 7 | 2015 | 209 | 0.800 |
Why?
|
Length of Stay | 4 | 2020 | 317 | 0.780 |
Why?
|
Social Media | 1 | 2021 | 27 | 0.760 |
Why?
|
Chest Pain | 1 | 2020 | 24 | 0.750 |
Why?
|
Intersectoral Collaboration | 1 | 2020 | 9 | 0.750 |
Why?
|
Endothelium | 1 | 2020 | 12 | 0.740 |
Why?
|
Brain Ischemia | 1 | 2021 | 71 | 0.740 |
Why?
|
Vascular Diseases | 1 | 2020 | 48 | 0.720 |
Why?
|
Patient Care Management | 2 | 2021 | 18 | 0.720 |
Why?
|
Takotsubo Cardiomyopathy | 1 | 2019 | 12 | 0.720 |
Why?
|
Treatment Outcome | 14 | 2023 | 3478 | 0.710 |
Why?
|
Cardiomyopathies | 1 | 2019 | 29 | 0.710 |
Why?
|
Ambulatory Care Facilities | 2 | 2022 | 37 | 0.700 |
Why?
|
Myxoma | 1 | 2019 | 6 | 0.700 |
Why?
|
Heart Neoplasms | 1 | 2019 | 13 | 0.700 |
Why?
|
Comorbidity | 5 | 2021 | 498 | 0.690 |
Why?
|
Heart Diseases | 1 | 2020 | 73 | 0.680 |
Why?
|
Heart Failure, Diastolic | 1 | 2018 | 2 | 0.680 |
Why?
|
Age Factors | 8 | 2021 | 843 | 0.680 |
Why?
|
Betacoronavirus | 1 | 2020 | 75 | 0.670 |
Why?
|
Women's Health Services | 1 | 2018 | 12 | 0.670 |
Why?
|
Hypertension | 7 | 2023 | 266 | 0.670 |
Why?
|
Prevalence | 6 | 2020 | 487 | 0.670 |
Why?
|
Culturally Competent Care | 1 | 2018 | 9 | 0.660 |
Why?
|
Heart Ventricles | 1 | 2019 | 170 | 0.660 |
Why?
|
Delivery of Health Care, Integrated | 1 | 2018 | 26 | 0.660 |
Why?
|
Warfarin | 3 | 2016 | 37 | 0.650 |
Why?
|
Emigrants and Immigrants | 1 | 2018 | 20 | 0.650 |
Why?
|
Coronavirus Infections | 1 | 2020 | 86 | 0.640 |
Why?
|
Pneumonia, Viral | 1 | 2020 | 89 | 0.640 |
Why?
|
Antineoplastic Agents | 1 | 2020 | 218 | 0.630 |
Why?
|
Atherosclerosis | 1 | 2018 | 72 | 0.610 |
Why?
|
Lipoprotein(a) | 1 | 2016 | 5 | 0.570 |
Why?
|
Prognosis | 7 | 2021 | 840 | 0.560 |
Why?
|
Cognition | 3 | 2020 | 1277 | 0.560 |
Why?
|
Dyslipidemias | 1 | 2016 | 23 | 0.550 |
Why?
|
Electrodes | 1 | 2015 | 16 | 0.530 |
Why?
|
Diabetes Mellitus | 3 | 2022 | 138 | 0.530 |
Why?
|
Health Knowledge, Attitudes, Practice | 2 | 2022 | 194 | 0.530 |
Why?
|
Secondary Prevention | 3 | 2022 | 64 | 0.520 |
Why?
|
Cost of Illness | 1 | 2015 | 54 | 0.510 |
Why?
|
Social Support | 1 | 2016 | 185 | 0.510 |
Why?
|
Patient Readmission | 3 | 2019 | 123 | 0.480 |
Why?
|
Electric Countershock | 6 | 2020 | 29 | 0.470 |
Why?
|
Adult | 15 | 2023 | 8601 | 0.470 |
Why?
|
Magnetic Resonance Imaging | 1 | 2019 | 1221 | 0.470 |
Why?
|
Aspirin | 2 | 2020 | 83 | 0.470 |
Why?
|
Aortic Valve | 3 | 2023 | 22 | 0.470 |
Why?
|
Aged, 80 and over | 9 | 2021 | 4851 | 0.470 |
Why?
|
Retrospective Studies | 10 | 2022 | 3273 | 0.450 |
Why?
|
Non-ST Elevated Myocardial Infarction | 3 | 2022 | 3 | 0.450 |
Why?
|
ST Elevation Myocardial Infarction | 3 | 2022 | 10 | 0.440 |
Why?
|
Atrial Appendage | 2 | 2022 | 45 | 0.410 |
Why?
|
Coronary Angiography | 3 | 2020 | 91 | 0.410 |
Why?
|
Patient Acceptance of Health Care | 1 | 2012 | 79 | 0.410 |
Why?
|
Alzheimer Disease | 1 | 2023 | 1942 | 0.390 |
Why?
|
Frailty | 2 | 2022 | 38 | 0.380 |
Why?
|
Cardiovascular Agents | 2 | 2021 | 28 | 0.370 |
Why?
|
Cross-Sectional Studies | 5 | 2022 | 959 | 0.360 |
Why?
|
Cardiac Resynchronization Therapy Devices | 2 | 2019 | 8 | 0.360 |
Why?
|
Feasibility Studies | 2 | 2020 | 227 | 0.350 |
Why?
|
Hospital Costs | 2 | 2020 | 68 | 0.350 |
Why?
|
Biomarkers | 4 | 2022 | 689 | 0.340 |
Why?
|
Practice Guidelines as Topic | 3 | 2021 | 333 | 0.330 |
Why?
|
Ventricular Fibrillation | 2 | 2021 | 30 | 0.310 |
Why?
|
Heart Atria | 2 | 2019 | 71 | 0.310 |
Why?
|
Percutaneous Coronary Intervention | 3 | 2022 | 23 | 0.310 |
Why?
|
Cohort Studies | 5 | 2023 | 1939 | 0.280 |
Why?
|
Health Status | 2 | 2018 | 227 | 0.270 |
Why?
|
Administration, Oral | 3 | 2016 | 140 | 0.270 |
Why?
|
Randomized Controlled Trials as Topic | 5 | 2020 | 340 | 0.270 |
Why?
|
Sex Distribution | 3 | 2019 | 87 | 0.260 |
Why?
|
Societies, Medical | 3 | 2023 | 190 | 0.260 |
Why?
|
Antihypertensive Agents | 2 | 2020 | 85 | 0.260 |
Why?
|
Hemorrhage | 5 | 2020 | 75 | 0.260 |
Why?
|
Risk Adjustment | 2 | 2021 | 12 | 0.250 |
Why?
|
Palliative Care | 2 | 2023 | 145 | 0.250 |
Why?
|
Obesity | 4 | 2020 | 291 | 0.240 |
Why?
|
Incidence | 4 | 2020 | 756 | 0.240 |
Why?
|
Logistic Models | 3 | 2021 | 407 | 0.240 |
Why?
|
Hospital Charges | 2 | 2020 | 17 | 0.240 |
Why?
|
Leadership | 2 | 2022 | 96 | 0.240 |
Why?
|
Young Adult | 3 | 2020 | 1932 | 0.240 |
Why?
|
Illinois | 2 | 2021 | 241 | 0.240 |
Why?
|
Cardiotoxicity | 2 | 2020 | 5 | 0.230 |
Why?
|
Minority Groups | 1 | 2023 | 67 | 0.230 |
Why?
|
Pulmonary Veins | 1 | 2023 | 23 | 0.230 |
Why?
|
Age Distribution | 2 | 2020 | 94 | 0.230 |
Why?
|
Cost-Benefit Analysis | 2 | 2022 | 144 | 0.230 |
Why?
|
Maternal Mortality | 1 | 2023 | 4 | 0.230 |
Why?
|
Morbidity | 2 | 2019 | 63 | 0.230 |
Why?
|
Health Promotion | 2 | 2016 | 161 | 0.220 |
Why?
|
Death | 1 | 2023 | 48 | 0.220 |
Why?
|
Out-of-Hospital Cardiac Arrest | 1 | 2022 | 8 | 0.220 |
Why?
|
Philippines | 1 | 2022 | 5 | 0.220 |
Why?
|
Pregnancy Outcome | 1 | 2022 | 20 | 0.220 |
Why?
|
Pregnant Women | 1 | 2022 | 12 | 0.220 |
Why?
|
Cesarean Section | 1 | 2022 | 30 | 0.210 |
Why?
|
Attitude | 1 | 2022 | 29 | 0.210 |
Why?
|
Adolescent | 2 | 2020 | 2279 | 0.210 |
Why?
|
Polypharmacy | 1 | 2022 | 10 | 0.210 |
Why?
|
Vitamin K | 1 | 2022 | 8 | 0.210 |
Why?
|
Sotalol | 1 | 2021 | 11 | 0.210 |
Why?
|
Venous Thromboembolism | 1 | 2022 | 37 | 0.210 |
Why?
|
Coronary Circulation | 2 | 2020 | 43 | 0.210 |
Why?
|
Cardiac Electrophysiology | 1 | 2021 | 3 | 0.210 |
Why?
|
Prospective Studies | 3 | 2023 | 1811 | 0.210 |
Why?
|
Pandemics | 2 | 2023 | 236 | 0.210 |
Why?
|
Troponin | 1 | 2021 | 7 | 0.210 |
Why?
|
Shock, Cardiogenic | 1 | 2021 | 10 | 0.200 |
Why?
|
Sexism | 1 | 2021 | 8 | 0.200 |
Why?
|
Diagnostic Techniques, Cardiovascular | 1 | 2021 | 2 | 0.200 |
Why?
|
Water-Electrolyte Imbalance | 1 | 2021 | 2 | 0.200 |
Why?
|
Telemedicine | 1 | 2023 | 99 | 0.200 |
Why?
|
Hormones | 1 | 2021 | 13 | 0.200 |
Why?
|
Sleep Apnea, Obstructive | 1 | 2022 | 52 | 0.200 |
Why?
|
Death, Sudden, Cardiac | 1 | 2021 | 20 | 0.200 |
Why?
|
Overweight | 1 | 2022 | 65 | 0.200 |
Why?
|
Alcohol Drinking | 1 | 2022 | 78 | 0.200 |
Why?
|
Women's Rights | 1 | 2021 | 2 | 0.200 |
Why?
|
Weight Loss | 1 | 2022 | 99 | 0.200 |
Why?
|
National Institutes of Health (U.S.) | 1 | 2021 | 30 | 0.200 |
Why?
|
Angioplasty | 1 | 2020 | 5 | 0.200 |
Why?
|
Signal Processing, Computer-Assisted | 2 | 1998 | 38 | 0.200 |
Why?
|
Peripheral Arterial Disease | 1 | 2020 | 10 | 0.200 |
Why?
|
Physician-Patient Relations | 1 | 2021 | 39 | 0.190 |
Why?
|
Health Expenditures | 1 | 2020 | 19 | 0.190 |
Why?
|
Career Choice | 1 | 2021 | 30 | 0.190 |
Why?
|
Heart Valve Diseases | 1 | 2020 | 22 | 0.190 |
Why?
|
Hyperlipidemias | 1 | 2020 | 19 | 0.190 |
Why?
|
Disease Outbreaks | 1 | 2021 | 88 | 0.190 |
Why?
|
Postoperative Hemorrhage | 1 | 2020 | 24 | 0.190 |
Why?
|
Periodicals as Topic | 1 | 2021 | 41 | 0.190 |
Why?
|
Endovascular Procedures | 1 | 2020 | 33 | 0.190 |
Why?
|
Myocardial Revascularization | 1 | 2020 | 18 | 0.190 |
Why?
|
Postnatal Care | 1 | 2020 | 7 | 0.190 |
Why?
|
Accidental Falls | 1 | 2022 | 116 | 0.190 |
Why?
|
Delivery, Obstetric | 1 | 2020 | 14 | 0.190 |
Why?
|
Heart Valve Prosthesis Implantation | 1 | 2020 | 22 | 0.190 |
Why?
|
Radiation-Protective Agents | 1 | 2020 | 3 | 0.190 |
Why?
|
Protective Factors | 1 | 2020 | 17 | 0.190 |
Why?
|
Colchicine | 1 | 2020 | 10 | 0.180 |
Why?
|
Infant, Newborn | 1 | 2022 | 604 | 0.180 |
Why?
|
Social Class | 1 | 2020 | 64 | 0.180 |
Why?
|
Prostatic Neoplasms | 1 | 2021 | 106 | 0.180 |
Why?
|
Income | 1 | 2020 | 74 | 0.180 |
Why?
|
Odds Ratio | 2 | 2020 | 285 | 0.180 |
Why?
|
Thrombolytic Therapy | 1 | 2020 | 56 | 0.180 |
Why?
|
After-Hours Care | 1 | 2019 | 1 | 0.180 |
Why?
|
Radiation Injuries | 1 | 2020 | 34 | 0.180 |
Why?
|
Global Health | 1 | 2019 | 55 | 0.180 |
Why?
|
Up-Regulation | 2 | 2021 | 174 | 0.180 |
Why?
|
Clinical Trials as Topic | 1 | 2021 | 324 | 0.180 |
Why?
|
Health Behavior | 1 | 2020 | 159 | 0.180 |
Why?
|
Multimodal Imaging | 1 | 2019 | 20 | 0.180 |
Why?
|
Cardiac Resynchronization Therapy | 1 | 2019 | 21 | 0.180 |
Why?
|
Heart | 1 | 2019 | 91 | 0.170 |
Why?
|
Treatment Refusal | 1 | 2018 | 13 | 0.170 |
Why?
|
Heart Transplantation | 1 | 1998 | 38 | 0.170 |
Why?
|
Asia, Western | 1 | 2018 | 2 | 0.170 |
Why?
|
Indian Ocean Islands | 1 | 2018 | 2 | 0.170 |
Why?
|
Surveys and Questionnaires | 3 | 2022 | 1184 | 0.170 |
Why?
|
Procainamide | 1 | 1998 | 23 | 0.160 |
Why?
|
Intensive Care Units | 1 | 2021 | 301 | 0.160 |
Why?
|
Atrial Flutter | 1 | 1998 | 20 | 0.160 |
Why?
|
Walking | 1 | 2020 | 252 | 0.160 |
Why?
|
Graft Rejection | 1 | 1998 | 76 | 0.160 |
Why?
|
Reproducibility of Results | 3 | 2017 | 788 | 0.160 |
Why?
|
Tachycardia | 2 | 2021 | 48 | 0.160 |
Why?
|
Sulfonamides | 1 | 1998 | 54 | 0.160 |
Why?
|
Diagnosis, Differential | 1 | 2019 | 389 | 0.160 |
Why?
|
Memory Disorders | 1 | 2019 | 174 | 0.160 |
Why?
|
Inpatients | 1 | 2019 | 141 | 0.160 |
Why?
|
Coronary Disease | 2 | 2020 | 86 | 0.150 |
Why?
|
Patient Discharge | 1 | 2018 | 149 | 0.150 |
Why?
|
Diet Surveys | 1 | 2017 | 19 | 0.150 |
Why?
|
Nutrition Assessment | 1 | 2017 | 31 | 0.150 |
Why?
|
Lupus Erythematosus, Systemic | 1 | 2020 | 202 | 0.150 |
Why?
|
Rivaroxaban | 1 | 2016 | 8 | 0.150 |
Why?
|
Dabigatran | 1 | 2016 | 7 | 0.150 |
Why?
|
Neoplasms | 1 | 2020 | 247 | 0.150 |
Why?
|
Pyridones | 1 | 2016 | 13 | 0.150 |
Why?
|
Evidence-Based Medicine | 1 | 2018 | 208 | 0.150 |
Why?
|
Echocardiography | 4 | 2023 | 172 | 0.150 |
Why?
|
Evidence-Based Practice | 1 | 2017 | 77 | 0.150 |
Why?
|
Thiazoles | 1 | 2016 | 35 | 0.150 |
Why?
|
Pyridines | 1 | 2016 | 42 | 0.150 |
Why?
|
Patient Selection | 2 | 2020 | 232 | 0.140 |
Why?
|
Dementia | 1 | 2022 | 521 | 0.140 |
Why?
|
Coronary Vessels | 2 | 2021 | 46 | 0.140 |
Why?
|
Georgia | 1 | 2016 | 12 | 0.140 |
Why?
|
Sensitivity and Specificity | 2 | 2015 | 553 | 0.140 |
Why?
|
Platelet Aggregation Inhibitors | 1 | 2016 | 49 | 0.140 |
Why?
|
Cholesterol, LDL | 1 | 2016 | 30 | 0.140 |
Why?
|
Pyrazoles | 1 | 2016 | 44 | 0.140 |
Why?
|
Diet, Mediterranean | 1 | 2017 | 62 | 0.140 |
Why?
|
Health Surveys | 1 | 2016 | 96 | 0.140 |
Why?
|
Self Efficacy | 1 | 2016 | 57 | 0.140 |
Why?
|
Chicago | 2 | 2016 | 865 | 0.140 |
Why?
|
Miniaturization | 1 | 2015 | 2 | 0.130 |
Why?
|
Preventive Health Services | 1 | 2015 | 15 | 0.130 |
Why?
|
Equipment Design | 2 | 2015 | 185 | 0.130 |
Why?
|
Heart Rate | 2 | 2009 | 142 | 0.130 |
Why?
|
Equipment Failure Analysis | 1 | 2015 | 106 | 0.130 |
Why?
|
Smoking | 2 | 2018 | 194 | 0.120 |
Why?
|
Needs Assessment | 1 | 2013 | 47 | 0.120 |
Why?
|
Cardiac Pacing, Artificial | 2 | 1992 | 81 | 0.110 |
Why?
|
Drug Monitoring | 1 | 2012 | 24 | 0.110 |
Why?
|
Heart Conduction System | 1 | 1992 | 32 | 0.110 |
Why?
|
Activities of Daily Living | 1 | 2016 | 501 | 0.110 |
Why?
|
Data Collection | 1 | 2012 | 107 | 0.110 |
Why?
|
Registries | 3 | 2022 | 188 | 0.110 |
Why?
|
Blood Pressure | 2 | 2023 | 238 | 0.090 |
Why?
|
Motor Activity | 1 | 2013 | 369 | 0.090 |
Why?
|
Coronary Artery Bypass | 2 | 2020 | 32 | 0.090 |
Why?
|
Survival Rate | 2 | 2019 | 349 | 0.080 |
Why?
|
Databases, Factual | 2 | 2019 | 330 | 0.080 |
Why?
|
Azetidines | 1 | 2006 | 2 | 0.070 |
Why?
|
Benzylamines | 1 | 2006 | 11 | 0.070 |
Why?
|
Severity of Illness Index | 2 | 2021 | 1113 | 0.070 |
Why?
|
Time Factors | 3 | 2021 | 1616 | 0.070 |
Why?
|
Body Mass Index | 2 | 2020 | 428 | 0.070 |
Why?
|
Endpoint Determination | 1 | 2004 | 28 | 0.060 |
Why?
|
Blood Pressure Monitoring, Ambulatory | 1 | 2023 | 5 | 0.060 |
Why?
|
Pharmacists | 1 | 2023 | 16 | 0.060 |
Why?
|
Postoperative Complications | 2 | 2020 | 957 | 0.060 |
Why?
|
Follow-Up Studies | 2 | 2019 | 1830 | 0.060 |
Why?
|
Urokinase-Type Plasminogen Activator | 1 | 2022 | 5 | 0.060 |
Why?
|
Receptors, Urokinase Plasminogen Activator | 1 | 2022 | 41 | 0.050 |
Why?
|
Double-Blind Method | 2 | 2006 | 503 | 0.050 |
Why?
|
Flecainide | 1 | 2021 | 14 | 0.050 |
Why?
|
Genetic Testing | 1 | 2022 | 64 | 0.050 |
Why?
|
Microcirculation | 1 | 2021 | 37 | 0.050 |
Why?
|
Ischemia | 1 | 2021 | 27 | 0.050 |
Why?
|
Delivery of Health Care | 1 | 2023 | 152 | 0.050 |
Why?
|
Peripartum Period | 1 | 2021 | 3 | 0.050 |
Why?
|
Pregnancy, High-Risk | 1 | 2021 | 3 | 0.050 |
Why?
|
Chlorides | 1 | 2021 | 24 | 0.050 |
Why?
|
Diuretics | 1 | 2021 | 15 | 0.050 |
Why?
|
Recurrence | 2 | 2006 | 350 | 0.050 |
Why?
|
Health Services Research | 1 | 2021 | 41 | 0.050 |
Why?
|
Sodium | 1 | 2021 | 76 | 0.050 |
Why?
|
Hypercholesterolemia | 1 | 2020 | 29 | 0.050 |
Why?
|
Vascular Endothelial Growth Factor A | 1 | 2020 | 65 | 0.050 |
Why?
|
Patient Preference | 1 | 2021 | 33 | 0.050 |
Why?
|
Fetal Growth Retardation | 1 | 2020 | 2 | 0.050 |
Why?
|
Polycystic Ovary Syndrome | 1 | 2020 | 3 | 0.050 |
Why?
|
Abortion, Spontaneous | 1 | 2020 | 9 | 0.050 |
Why?
|
Education, Medical | 1 | 2021 | 49 | 0.050 |
Why?
|
Menopause, Premature | 1 | 2020 | 7 | 0.050 |
Why?
|
Lactation | 1 | 2021 | 62 | 0.050 |
Why?
|
Case-Control Studies | 2 | 2000 | 638 | 0.050 |
Why?
|
Sleep Apnea, Central | 1 | 2000 | 25 | 0.050 |
Why?
|
Clinical Decision-Making | 1 | 2020 | 36 | 0.050 |
Why?
|
Health Care Costs | 1 | 2020 | 70 | 0.050 |
Why?
|
Attitude to Health | 1 | 2020 | 97 | 0.050 |
Why?
|
Radiotherapy | 1 | 2020 | 50 | 0.050 |
Why?
|
Curriculum | 1 | 2021 | 155 | 0.050 |
Why?
|
Costs and Cost Analysis | 1 | 2019 | 36 | 0.040 |
Why?
|
Autoimmune Diseases | 1 | 2020 | 61 | 0.040 |
Why?
|
Thrombectomy | 1 | 2019 | 27 | 0.040 |
Why?
|
Cause of Death | 1 | 2019 | 65 | 0.040 |
Why?
|
Multivariate Analysis | 1 | 2020 | 324 | 0.040 |
Why?
|
Disease Management | 1 | 2020 | 114 | 0.040 |
Why?
|
Psychology | 1 | 2018 | 20 | 0.040 |
Why?
|
Health Services Needs and Demand | 1 | 2018 | 53 | 0.040 |
Why?
|
Heredity | 1 | 2018 | 6 | 0.040 |
Why?
|
Cancer Survivors | 1 | 2018 | 10 | 0.040 |
Why?
|
Diabetes Mellitus, Type 2 | 1 | 2020 | 200 | 0.040 |
Why?
|
Diet, Western | 1 | 2017 | 6 | 0.040 |
Why?
|
Quality Improvement | 1 | 2018 | 158 | 0.040 |
Why?
|
Breast Feeding | 1 | 2018 | 155 | 0.040 |
Why?
|
Body Composition | 1 | 2016 | 56 | 0.030 |
Why?
|
Waist Circumference | 1 | 2015 | 36 | 0.030 |
Why?
|
Risk | 1 | 2016 | 217 | 0.030 |
Why?
|
Drug Therapy, Combination | 1 | 2016 | 241 | 0.030 |
Why?
|
Body Weight | 1 | 2016 | 133 | 0.030 |
Why?
|
Decision Making | 1 | 2018 | 220 | 0.030 |
Why?
|
Genetic Predisposition to Disease | 1 | 2018 | 441 | 0.030 |
Why?
|
Patient Compliance | 1 | 2016 | 164 | 0.030 |
Why?
|
Wolff-Parkinson-White Syndrome | 1 | 1993 | 3 | 0.030 |
Why?
|
Dextroamphetamine | 1 | 1993 | 6 | 0.030 |
Why?
|
Social Networking | 1 | 2013 | 10 | 0.030 |
Why?
|
Syncope | 1 | 1993 | 8 | 0.030 |
Why?
|
Hypotension, Orthostatic | 1 | 1993 | 16 | 0.030 |
Why?
|
Efficiency | 1 | 2013 | 15 | 0.030 |
Why?
|
Albuterol | 1 | 1993 | 15 | 0.030 |
Why?
|
Bradycardia | 1 | 1993 | 28 | 0.030 |
Why?
|
Interviews as Topic | 1 | 2013 | 130 | 0.030 |
Why?
|
Program Evaluation | 1 | 2013 | 132 | 0.030 |
Why?
|
Tachycardia, Ventricular | 1 | 1992 | 34 | 0.030 |
Why?
|
Cardiac Catheterization | 1 | 1992 | 89 | 0.030 |
Why?
|
Asthma | 1 | 1993 | 138 | 0.020 |
Why?
|
Animals | 1 | 2020 | 4552 | 0.020 |
Why?
|
Chemical and Drug Induced Liver Injury | 1 | 2006 | 13 | 0.020 |
Why?
|
Estrogen Replacement Therapy | 1 | 2006 | 20 | 0.020 |
Why?
|
Thromboembolism | 1 | 2006 | 18 | 0.020 |
Why?
|
Chi-Square Distribution | 1 | 2006 | 145 | 0.020 |
Why?
|
Proportional Hazards Models | 1 | 2006 | 340 | 0.020 |
Why?
|
Combined Modality Therapy | 1 | 2004 | 364 | 0.010 |
Why?
|
Electrocardiography, Ambulatory | 1 | 2000 | 21 | 0.010 |
Why?
|
Bronchoscopy | 1 | 2000 | 25 | 0.010 |
Why?
|
Tracheostomy | 1 | 2000 | 19 | 0.010 |
Why?
|
Respiration | 1 | 2000 | 35 | 0.010 |
Why?
|
Anesthesia | 1 | 2000 | 34 | 0.010 |
Why?
|
Child | 1 | 2000 | 1346 | 0.010 |
Why?
|
False Positive Reactions | 1 | 1993 | 33 | 0.010 |
Why?
|
Administration, Inhalation | 1 | 1993 | 25 | 0.010 |
Why?
|
Contraindications | 1 | 1993 | 41 | 0.010 |
Why?
|
Posture | 1 | 1993 | 78 | 0.010 |
Why?
|
Action Potentials | 1 | 1993 | 136 | 0.010 |
Why?
|
ROC Curve | 1 | 1992 | 138 | 0.010 |
Why?
|
Analysis of Variance | 1 | 1992 | 321 | 0.010 |
Why?
|